Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Elisa Agostinetto MD

Elisa Agostinetto MD

Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium

Dr. Elisa Agostinetto is a medical oncologist and researcher in the field of breast cancer. She earned her medical degree in Italy, at University of Udine. She completed her training in medical oncology in Milan, Italy, and afterwards she moved to Brussels, Belgium, where she is currently pursuing an advanced research fellowship at Institut Jules Bordet - Université Libre de Bruxelles.

She is a member of the European Society of Medical Oncology (ESMO), of the American Society of Clinical Oncology (ASCO), and of the Belgian Society of Medical Oncology (BSMO); she is a young investigator in the EORTC Breast Cancer Working Group, and she is a Steering Committee member of the Young Cancer Professionals within the European Cancer Organization.

She is author of more than 50 articles published in peer-reviewed scientific journals, including JAMA, Nature Reviews Clinical Oncology, Lancet Oncology, Annals of Oncology, European Journal of Cancer, and ESMO Open. Her research works have been presented in several international oncology conferences, including ASCO, ESMO and San Antonio Breast Cancer Symposium. She is the recipient of several prestigious national and international awards.

Disclosures

Speaking fee/honoraria from Eli Lilly, Sandoz, AstraZeneca; research grant to my Institution from Gilead; meeting/travel grants from Novartis, Roche, Eli Lilly, Genetic, Istituto Gentili, Daiichi Sankyo, AstraZeneca (all outside the submitted work).